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Clinical trials to evaluate patients affected by rare diseases are often hampered by the diffi-
culty of recruiting a critical sample size. Registries for rare conditions are thus extremely
powerful tools for overcoming recruitment problems. Here we present and discuss the interna-
tional experience with alpha1-antitrypsin deficiency achieved by the Alpha One International
Registry, and national experience obtained with a large series of patients with pulmonary alve-
olar proteinosis.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
The current definition of a rare disease is a medical
condition occurring in <50, 000 individuals among the
European general population. This implies that, for some of
these conditions, a general practitioner or even a specialist
may see only one or two cases during his/her professional
career. It is therefore conceivable that isolated patients
affected by a rare disorder managed by a single physician
will not contribute to progress in the understanding of the
epidemiology, pathophysiology, natural history and efficacy
of treatments for such disorders. However, when isolated
patients are included in large cohorts that are eventually423131; fax:þ39 0382 42267.
o.pv.it (M. Luisetti).
0 Elsevier Ltd. All rights reservedsubmitted to careful analysis we can greatly improve our
knowledge of these conditions.
Registries are powerful tools in improving our under-
standing of rare diseases. Taking advantage of our experi-
ence in two rare respiratory diseases: alpha1-antitrypsin
deficiency (AATD) and pulmonary alveolar proteinosis
(PAP), we describe how registries (or a large cohort of
patients) can help physicians to better manage the disease
and design clinical trials.AATD: the Alpha One International Registry
(AIR)
AATD is characterized by reduced blood levels of the serine
protease inhibitor alpha1-antitrypsin, leading to an increased
risk of developing pulmonary emphysema and chronic liver
disease. AATD is probably the most common inherited rare.
Clinical trials and registries in rare diseases S43disorder in Western countries.1 Even though the disorder was
identified for the first time in 1963, three decades later its
relative infrequency (1 in 1600e2000) is still the major hand-
icap to understanding and designing interventions.
In 1997 a World Health Organization meeting recom-
mended the establishment of national and international
registries to facilitate data collection and collaborative
research, and to help create a patient resource bank for the
design and conduct of suitably powered clinical trials.2 To
comply with these recommendations, the Alpha One
International Registry (AIR) was initiated with the following
four main objectives: 1) to establish an international
database of patients, including their demographic details;
2) to promote basic and clinical research on AATD and to
coordinate these activities; 3) to collect, assess and
disseminate information concerning all aspects of AATD;
and 4) to encourage the support and awareness of AATD.
Most of the aims of AIR have been now successfully
accomplished. Stockley and co-workers recently described
that by 2005 the registry included 21 countries from four
continents.3 A web-enabled questionnaire has been devel-
oped that may be completed online by authorized physi-
cians. Data quality is audited by the central AIR database
manager and a national delegate, who supervises all
national entries. By the time Stockley’s data was published
in 2007, a total of 2627 AATD individuals were enrolled in
AIR, which is the largest series of AATD individuals in the
world. Currently, more than 4000 AATD are included.
Another accomplishment concerns the successful
submission of proposals to the European Commission
Framework Project. Two projects were approved and fun-
ded by the 5th Framework Project: the Software Perfor-
mance and Reproducibility in Emphysema Assessment:
Demonstration (SPREAD) project (QLG1-2000-0152) and the
AIR genetics project (QLG2-2001-01021). The first repre-
sents a consortium of AIR investigators aiming to explore
lung densitometry assessed by computed tomography (CT)
as a possible outcome for longitudinal studies in pulmonary
emphysema.4 Of particular interest, the results obtained by
the consortium have been subsequently utilized in an AATD
clinical trial (see below).
The second project is very ambitious: to collect DNA
samples from AIR members’ PI*ZZ AATD siblings who
currently smoke, yet have discordant lung function, to
investigate the possible presence of genetic factor(s) other
than the AAT gene that may increase the risk of developing
emphysema or, alternatively, protect the lung from
emphysema development. It is a very long and labour-
intensive project: the cohort of siblings has been identi-
fied and DNA samples have been submitted to two runs of
genome-wide linkage analysis. Several linkage peaks have
been identified and, after fine mapping, candidate gene
analysis is currently in progress.
Anotherproject still inprogresswas fundedbytheECunder
the call of Public Health e 2006. Patient Associations and
Alpha1-antitrypsin Deficiency (PAAIR) is a project in which
patient support groups and national AATD registries from the
Netherlands,Germanyand Italywork together toevaluate the
impact of reference centres for AATD on morbidity and
mortality, and the outcomes of an effective collaboration.
A major goal of AIR has been to design clinical trials and
recruit AATD patients. In particular, two important trialshave been completedwith its help. One is theAATDbranch of
a trial aimed at evaluating the potential effectiveness of an
agonist of the g-retinoid receptor to prevent the progression
of emphysema, using CT scan densitometry as a measure of
efficacy. The trial in patients with AATD-associated emphy-
sema preceded on common emphysemawithout AATD, and is
currently in the final stage of data analysis. Another impor-
tant trial, which expanded a previous report,5 has been
completed and recently published. The study demonstrated
in 77AATDpatients recruitedamong thenational registries of
the UK, Denmark and Sweden, treated weekly with alpha1-
antitrypsin infusions for 2 years, that computed tomog-
raphywasmore sensitive than othermeasures of emphysema
progression, such as physiology and health status.6 Because
of its exploratory nature, the trial was not powered to
demonstrate the efficacy of the replacement therapy;
nevertheless, the densitometric analysis showed a trend
suggestive of treatment benefit.
It is important to reiterate that without organizations
like the AIR, clinical trials for rare diseases would practi-
cally never be conducted. Another relevant aspect is that
emphysema associated with AATD has been used to pioneer
the use of CT densitometry as an outcome in clinical trials.
It is conceivable that the treatment of emphysema in
common COPD will benefit from the experience gained in
AATD studies.Pulmonary alveolar proteinosis: not only rare
but also neglected
Pulmonary alveolar proteinosis (PAP) is an extremely rare
but ubiquitous syndrome (not a single disease) occurring at
all ages and characterized by the accumulation of surfactant
and surfactant by-products within the airspaces. A typical
feature of PAP is the variable clinical history, ranging from
spontaneous improvement or resolution, to progressive
respiratory failure. Inspite of the exceptional progress ach-
ieved in the understanding of the pathophysiology of PAP
during the last 15 years7 it is still a neglected condition, even
in Western countries. Some features of PAP and AATD in
Europe are compared in Table 1.
The history of PAP is marked by two important mile-
stones: the introduction of whole-lung lavage (WLL) to
clinical practice, and the discovery that PAP arises because
of disturbances in GM-CSF signalling. The first seminal
discovery had a direct impact on the natural history of PAP:
first characterized by a death rate of 30%, it was no longer
considered potentially fatal after the introduction of WLL
in the 1960s.8 From this point of view, WLL revolutionized
the course of PAP.
The discovery that GM-CSF played a crucial role in lung-
surfactant homeostasis, and subsequently that PAP cases
previously referred to as idiopathic or primary were
actually autoimmune disorders associated with the pres-
ence in the blood and lung of autoantibodies neutralizing
GM-CSF,9 opened the way to the potential use of exoge-
nous GM-CSF to treat PAP, especially in those cases
refractory to WLL or that could not be treated by this
invasive procedure.
An obvious difficulty in the design of a study to demon-
strate GM-CSF efficacy in PAP is the lack of disease
Table 1 Comparative features of alpha1-antitrypsin
deficiency (AATD) and pulmonary alveolar proteinosis (PAP)
in Europe.
AATD PAP
Incidence (n/100 000) 25 0.1
Included in national lists
for rare diseases
Yes Some
countries
National registries Yes No
International registry Yes No
Reference-centre network Yes No
Patient support groups Yes No
Therapy available (paid for by the
national health service)
Some
countries
No
S44 M. Luisetti et al.registries, such as those available in Europe and the USA for
AATD cases, which allow the recruitment of sufficient
cases. Nevertheless, inspite of the lack of structured
registries, large series of PAP cases have been assembled
through single or closely connected clinical sites.10,11 The
Japanese PAP series, the largest available worldwide, has
recently completed an open-label trial on GM-CSF aero-
solization in autoimmune PAP patients. At our centre in
Pavia, Italy we took advantage of the large series of PAP
patients made available over 20 years from the institutional
programme on WLL at the Fondazione IRCCS San Matteo
Hospital. Using this series we initiated a randomized trial
aimed at evaluating the superiority of WLL followed by
inhaled GM-CSF over WLL alone. The study, currently in
progress, includes the enrolment of 18 autoimmune PAP
patients over a 36-month period.12 To the best of our
knowledge this is the first randomized trial designed to
study PAP.Conclusions
Registries are extremely powerful tools to improve our
understanding of the natural history of rare disorders. In
addition they are extremely useful for recruiting patients
for clinical trials that otherwise could not be performed.
Thus, a critical issue for neglected rare diseases is to createnetworks of reference centres with the aim of establishing
national and international registries.Conflict of interest statement
The authors of this manuscript have no conflict of interest
to declare.
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